Eversept Partners, LP

13F Filings History

Latest 13F report
Q4 2024 - Feb 14, 2025
Value $
$969M
Signature - Title
Ron Rosenstraus - Chief Financial Officer
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by Eversept Partners, LP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Eversept Partners, LP reported 62 stock holdings with total value $969M as of Q4 2024. Top holdings included NTRA, GSK, VERA, INSP, and HCA.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q4 2024 62 $969M +$169M -$401M -$232M NTRA, GSK, VERA, INSP, HCA 13F-HR 2/14/2025, 10:13 AM
Q3 2024 65 $1.3B +$145M -$326M -$181M GSK, NTRA, VERA, INSM, SNDX 13F-HR 11/14/2024, 09:08 AM
Q2 2024 72 $1.31B +$256M -$269M -$12.4M GSK, NTRA, INSM, TEVA, UTHR 13F-HR 8/14/2024, 09:03 AM
Q1 2024 67 $1.34B +$248M -$159M +$89.9M NTRA, GSK, INSP, TEVA, VERA 13F-HR 5/15/2024, 08:40 AM
Q4 2023 55 $1.02B +$200M -$184M +$16.2M NTRA, GSK, SNDX, INSP, TEVA 13F-HR 2/14/2024, 08:50 AM
Q3 2023 83 $1.18B +$212M -$155M +$57.6M QQQ, GSK, NTRA, SPY, TEVA 13F-HR 11/14/2023, 02:07 PM
Q2 2023 80 $1.2B +$192M -$441M -$249M QQQ, NTRA, GSK, SPY, TEVA Restatement 11/8/2023, 02:50 PM
Q1 2023 82 $1.43B +$600M -$321M +$279M SPY, NTRA, QQQ, GSK, HZNP Restatement 11/8/2023, 02:48 PM
Q4 2022 4 $432K ELDN, SNDA, CTLT, BOLT New Holdings 11/8/2023, 02:46 PM
Q4 2022 87 $1.14B +$335M -$500M -$165M GSK, HZNP, NTRA, SNY, GSK Restatement 11/8/2023, 02:44 PM
Q3 2022 1 $673K CYH New Holdings 11/8/2023, 02:42 PM
Q3 2022 91 $1.15B +$456M -$660M -$203M QQQ, BHVNXXXX, GSK, HZNP, NTRA Restatement 11/8/2023, 02:40 PM
Q2 2022 1 $699K TEVA New Holdings 11/8/2023, 02:38 PM
Q2 2022 106 $1.41B +$584M -$324M +$260M SPY, BHVNXXXX, QQQ, UTHR, HZNP Restatement 11/8/2023, 02:37 PM
Q1 2022 118 $1.3B +$293M -$479M -$186M CYH, BHVNXXXX, GSKXXXX, QQQ, HZNP Restatement 11/8/2023, 02:35 PM
Q4 2021 2 $580K JYNT, MNKD New Holdings 11/8/2023, 02:33 PM
Q4 2021 89 $1.2B +$239M -$281M -$41.6M HZNP, CYH, UTHR, DHR, AZN Restatement 11/8/2023, 02:31 PM
Q3 2021 0 $0 $0 $0 New Holdings 11/8/2023, 02:29 PM
Q3 2021 88 $1.25B +$384M -$228M +$156M UTHR, ASND, CYH, HZNP, XLRN Restatement 11/8/2023, 02:28 PM
Q2 2021 69 $1.08B +$244M -$384M -$141M UTHR, AMRN, ARKG, HZNP, AZN Restatement 11/8/2023, 02:26 PM
Q1 2021 0 $0 $0 $0 New Holdings 11/8/2023, 02:23 PM
Q1 2021 74 $1.22B +$492M -$155M +$338M AMRN, UTHR, ARKG, ALXN, HZNP Restatement 11/8/2023, 02:21 PM
Q4 2020 2 $561K LCIXXXX, CYTK New Holdings 11/8/2023, 02:15 PM
Q4 2020 73 $852M +$427M -$145M +$281M AMRN, UTHR, ALXN, TGTX, AZN Restatement 11/8/2023, 02:13 PM
Q3 2020 1 $636K LCIXXXX New Holdings 11/8/2023, 02:10 PM
Q3 2020 79 $450M +$111M -$401M -$290M HZNP, AMRN, TGTX, ASND, UTHR Restatement 11/8/2023, 01:56 PM
Q2 2020 86 $729M +$359M -$181M +$178M SPY, HZNP, TGTX, AMRN, BHVNXXXX Restatement 11/8/2023, 01:52 PM
Q1 2020 86 $402M +$166M -$208M -$41.9M ZGNX, DHR, ASND, TGTX, APLS Restatement 11/8/2023, 01:50 PM
Q4 2019 83 $566M +$251M -$69.1M +$182M SPY, GSKXXXX, ENSG, DHR, ASND Restatement 11/8/2023, 01:47 PM
Q3 2019 76 $322M +$102M -$104M -$1.87M GSKXXXX, ENSG, DHR, ZGNX, ASND Restatement 11/8/2023, 01:45 PM
Q2 2019 73 $357M +$84.5M -$87M -$2.44M RCM, AMRN, GSKXXXX, ZGNX, DHR Restatement 11/8/2023, 01:39 PM
Q1 2019 72 $343M +$153M -$36.5M +$117M AMRN, GSKXXXX, RCM, ZGNX, DHR Restatement 11/8/2023, 01:38 PM
Q4 2018 76 $185M +$56.8M -$65.2M -$8.46M ZGNX, GSKXXXX, RCM, AMRN, SNY Restatement 11/8/2023, 01:36 PM
Q3 2018 90 $228M +$83.8M -$82.5M +$1.29M SPY, ZGNX, RCM, AMRN, SNY Restatement 11/8/2023, 01:33 PM
Q2 2018 80 $219M +$51.6M -$62.1M -$10.4M QCP, RCM, AERI, RDUS, GSKXXXX Restatement 11/8/2023, 01:31 PM
Q1 2018 68 $215M +$84.1M -$54.7M +$29.4M QCP, SPY, RCM, RDUS, AERI Restatement 11/8/2023, 01:29 PM
Q4 2017 46 $174M SPY, ARRY, AERI, ZGNX, VRTX Restatement 11/8/2023, 01:26 PM